The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

Trump administration funding cuts and dismantling of USAID force the focus to shift from elimination back to treatment.